Hepatitis B Prescriber Update

Hepatitis B Treatment Lag

Australia's Fourth National Hepatitis B Strategy 2023–2030 aims to eliminate the virus as a public health threat by 2030, yet recent data reveal the country trails its own benchmarks by more than a decade. Treatment uptake remains low, with just over 10% of the estimated 220,000 people living with chronic hepatitis B on antivirals, despite evidence that expanding access could halve liver cancer risk over four to five years.

Global momentum accelerated in 2024–2025 with updated WHO guidelines expanding treatment criteria—simplifying initiation for more patients, including those with lower viral loads or fibrosis thresholds—and similar evolutions in EASL 2025 guidelines emphasising earlier intervention to prevent disease progression. These shifts coincide with calls from Australian advocates for universal screening and broader eligibility to close gaps, particularly among priority populations like Aboriginal and Torres Strait Islander communities and migrants from high-prevalence regions.

The stakes are measured in lives: untreated chronic hepatitis B drives most cases of primary liver cancer in Australia, a leading cause of cancer death with poor survival rates once advanced. Low diagnosis (around 75,000 undiagnosed) and care engagement (only 23% in regular monitoring) compound risks, while PBS subsidies for drugs like entecavir and tenofovir remain tied to s100 prescriber authority—restricted to accredited GPs and nurse practitioners who must complete initial training and earn at least three hepatitis B-specific CPD points yearly.

Tensions arise from workforce constraints in rural areas, where prescriber shortages limit access, against pushes for primary care-led models that could scale treatment without overburdening specialists. Critics argue overly restrictive criteria delay care compared to international standards, while supporters of cautious expansion cite needs for monitoring to avoid unnecessary long-term antiviral use and resistance risks. Maintaining accreditation through updates like the February 2026 session ensures prescribers stay current amid these debates.